Сравнение
Amycretin vs. Semaglutid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
нет данных
910463-68-2
Молекулярная масса
нет данных
4113.6 g/mol
Период полувыведения
нет данных
165 h
Последовательность
нет данных
modifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerМеханизм действия
Amycretin
Amycretin activates both the GLP-1 and the amylin receptor in a single molecule. Both pathways independently suppress appetite and food intake — the combination is intended to amplify the effect beyond the GLP-1 axis alone.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
1
4
из них на людях
1
3
Зафиксированные эффекты
2
3
Открытые противоречия
0
1
Задокументированные нежелательные явления
1
5
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Amycretin and Semaglutid?
- Amycretin is classified as "Метаболизм", while Semaglutid is classified as "Метаболизм". Amycretin: Amycretin is a unimolecular GLP-1 and amylin receptor agonist from Novo Nordisk — in development both as a once-weekly subcutaneous and a once-daily oral form for obesity and type 2 diabetes. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Amycretin or Semaglutid?
- The highest available evidence level is "РКИ на людях" for Amycretin and "РКИ на людях" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Amycretin and Semaglutid in Germany and the United States?
- Германия: Amycretin — Не одобрено, Semaglutid — Рецептурный. США: Amycretin — Не одобрено, Semaglutid — Рецептурный. These are factual summaries with source and review date on the individual pages.